Po-Chang Shih, PhD
Affiliations: | 2015-2019 | Pharmaceutical & Bio Chemistry, School of Pharmacy | University College London, London, United Kingdom |
Area:
drug discovery, medicinal chemistryGoogle:
"Po-Chang Shih"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Gary Parkinson | grad student | 2015-2019 | UCL |
| Geoffrey Wells | grad student | 2015-2019 | UCL |
| Andy Wilderspin | grad student | 2015-2019 | UCL |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chiang YC, Selvam P, Liu YX, et al. (2024) STAT3 phosphorylation inhibitor Bt354 exhibits anti-neoplastic activity in glioblastoma multiforme cells. Environmental Toxicology |
| Shih PC, Naganuma M, Tsuji G, et al. (2023) Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3. Bioorganic & Medicinal Chemistry. 95: 117507 |
| Shih PC. (2022) The role of the STAT3 signaling transduction pathways in radioresistance. Pharmacology & Therapeutics. 234: 108118 |
| Shih PC, Mei KC. (2020) Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance. Drug Discovery Today |
| Shih PC. (2019) Revisiting the development of small molecular inhibitors that directly target the signal transducer and activator of transcription 3 (STAT3) domains. Life Sciences. 117241 |